more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks

by Tirthankar Chakraborty Published on May 26,2020

As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.

Tap the Solid Momentum in These 5 Solid High-Beta Stocks

by Sanghamitra Saha Published on May 26,2020

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

earnings

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

by Sanghamitra Saha Published on May 26,2020

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Coronavirus Vaccine Development Gathers Steam: 4 Winners

by Ritujay Ghosh Published on May 26,2020

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

by Ritujay Ghosh Published on May 22,2020

Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on May 21,2020

Is (MRNA) Outperforming Other Medical Stocks This Year?

MRNANegative Net Change

Company News for May 21, 2020

by Zacks Equity Research Published on May 21,2020

Companies In The News Are: MRNA, FB, CLX, RCL.

Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

by Sweta Jaiswal, FRM Published on May 20,2020

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

by Zacks Equity Research Published on May 20,2020

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

biotechs

Stock Market News for May 20, 2020

by Zacks Equity Research Published on May 20,2020

U.S. stock markets closed lower on Tuesday following the news that a potential vaccine candidate for the treatment of the coronavirus may not be effective.

Moderna Declines on Skepticism on Coronavirus Vaccine Data

by Zacks Equity Research Published on May 20,2020

Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.

biotechs

Moderna Rallies on Encouraging Coronavirus Vaccine Study Data

by Zacks Equity Research Published on May 19,2020

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

biotechs

Stock Market News for May 19, 2020

by Zacks Equity Research Published on May 19,2020

Wall Street rebounded impressively on Monday buoyed by an encouraging early-stage clinical trial data for a potential coronavirus vaccine.

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

by Ritujay Ghosh Published on May 19,2020

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Major Indexes Defying "Sell in May" Adage: 5 Growth Picks

by Nalak Das Published on May 19,2020

Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."

Here's Why Moderna (MRNA) Stock is Jumping Today

by Madeleine Johnson Published on May 18,2020

On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.

Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?

by Benjamin Rains Published on May 18,2020

We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...